Literature DB >> 28062513

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

Cara L Haymaker1, DaeWon Kim1, Marc Uemura1, Luis M Vence2, Ann Phillip1, Natalie McQuail1, Paul D Brown3, Irina Fernandez2, Courtney W Hudgens4, Caitlin Creasy1, Wen-Jen Hwu1, Padmanee Sharma2, Michael T Tetzlaff4,5, James P Allison2, Patrick Hwu1, Chantale Bernatchez6, Adi Diab6.   

Abstract

We report here on a patient with metastatic melanoma who had extensive brain metastases. After being treated with the sequential combination of whole brain radiation therapy followed by the PD-1-inhibitory antibody, pembrolizumab, the patient had a durable complete response. Retrospective laboratory studies of T cells revealed that, after treatment with anti-PD-1 commenced, effector CD8+ T cells in the blood expanded and the ratio of CD8+:Treg T cells increased. A CD8+ T-cell clone present in the initial brain metastases was expanded in the blood after anti-PD-1 treatment, which suggested an antitumor role for this clone. Immunohistochemical analysis confirmed the presence of CD8+ T cells and low PD-L1 expression in the brain metastases before immunotherapy initiation. This sequence of therapy may provide an option for melanoma patients with unresponsive brain metastases. Cancer Immunol Res; 5(2); 100-5. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28062513      PMCID: PMC7055516          DOI: 10.1158/2326-6066.CIR-16-0223

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  23 in total

1.  Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.

Authors:  Harlan S Robins; Paulo V Campregher; Santosh K Srivastava; Abigail Wacher; Cameron J Turtle; Orsalem Kahsai; Stanley R Riddell; Edus H Warren; Christopher S Carlson
Journal:  Blood       Date:  2009-08-25       Impact factor: 22.113

2.  Aging attenuates radiation-induced expression of pro-inflammatory mediators in rat brain.

Authors:  Won Hee Lee; William E Sonntag; Yong Woo Lee
Journal:  Neurosci Lett       Date:  2010-04-10       Impact factor: 3.046

3.  Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.

Authors:  M H Amer; M Al-Sarraf; L H Baker; V K Vaitkevicius
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

4.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

Authors:  Kim Margolin; Marc S Ernstoff; Omid Hamid; Donald Lawrence; David McDermott; Igor Puzanov; Jedd D Wolchok; Joseph I Clark; Mario Sznol; Theodore F Logan; Jon Richards; Tracy Michener; Agnes Balogh; Kevin N Heller; F Stephen Hodi
Journal:  Lancet Oncol       Date:  2012-03-27       Impact factor: 41.316

5.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

6.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

Authors:  Leo J Schouten; Joost Rutten; Hans A M Huveneers; Albert Twijnstra
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

7.  Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.

Authors:  Jeffrey J Raizer; Wen-Jen Hwu; Katherine S Panageas; Andrew Wilton; Drew E Baldwin; Elizabeth Bailey; Caroline von Althann; Lynne A Lamb; Gladys Alvarado; Mark H Bilsky; Philip H Gutin
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

8.  PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.

Authors:  Weiyi Peng; Chengwen Liu; Chunyu Xu; Yanyan Lou; Jieqing Chen; Yan Yang; Hideo Yagita; Willem W Overwijk; Gregory Lizée; Laszlo Radvanyi; Patrick Hwu
Journal:  Cancer Res       Date:  2012-08-20       Impact factor: 12.701

9.  Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

Authors:  Wenshi Wang; Daohai Yu; Amod A Sarnaik; Bin Yu; Maclean Hall; Dawn Morelli; Yonghong Zhang; Xiuhua Zhao; Jeffrey S Weber
Journal:  J Transl Med       Date:  2012-07-12       Impact factor: 5.531

10.  Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma.

Authors:  Henrik Hauswald; Jan-Oliver Dittmar; Daniel Habermehl; Stefan Rieken; Florian Sterzing; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2012-08-02       Impact factor: 3.481

View more
  27 in total

Review 1.  The Reciprocity between Radiotherapy and Cancer Immunotherapy.

Authors:  Yifan Wang; Zhi-Gang Liu; Hengfeng Yuan; Weiye Deng; Jing Li; Yuhui Huang; Betty Y S Kim; Michael D Story; Wen Jiang
Journal:  Clin Cancer Res       Date:  2018-11-09       Impact factor: 12.531

2.  Immune System in Action.

Authors:  Bettzy Stephen; Joud Hajjar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.

Authors:  Mengjia Song; Xinfeng Chen; Liping Wang; Yi Zhang
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

Review 4.  The Significance of Tumor Necrosis Factor Receptor Type II in CD8+ Regulatory T Cells and CD8+ Effector T Cells.

Authors:  Lin-Lin Ye; Xiao-Shan Wei; Min Zhang; Yi-Ran Niu; Qiong Zhou
Journal:  Front Immunol       Date:  2018-03-22       Impact factor: 7.561

Review 5.  Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.

Authors:  Kazuma Kiyotani; Hiu Ting Chan; Yusuke Nakamura
Journal:  Cancer Sci       Date:  2018-02-14       Impact factor: 6.716

Review 6.  The emerging role of epigenetic therapeutics in immuno-oncology.

Authors:  Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2019-09-23       Impact factor: 66.675

Review 7.  The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.

Authors:  Kimberly M Arnold; Nicole J Flynn; Adam Raben; Lindsay Romak; Yan Yu; Adam P Dicker; Firas Mourtada; Jennifer Sims-Mourtada
Journal:  Cancer Growth Metastasis       Date:  2018-03-09

Review 8.  Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature.

Authors:  Jin-Cheng Song; Xiao-Lei Ding; Xiu-Hua Sun; Mohammed Safi; Juan Tian
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 9.  Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.

Authors:  Yifan Wang; Weiye Deng; Nan Li; Shinya Neri; Amrish Sharma; Wen Jiang; Steven H Lin
Journal:  Front Pharmacol       Date:  2018-03-05       Impact factor: 5.810

10.  Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.

Authors:  Mary Jo Turk; Christina V Angeles; Jichang Han; Yanding Zhao; Keisuke Shirai; Aleksey Molodtsov; Fred W Kolling; Jan L Fisher; Peisheng Zhang; Shaofeng Yan; Tyler G Searles; Justin M Bader; Jiang Gui; Chao Cheng; Marc S Ernstoff
Journal:  Nat Cancer       Date:  2021-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.